A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

OBJECTIVE: A randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate Alzheimer disease (AD) examined its safety and tolerability and effects on biomarker (plasma Aβ40 and Aβ42, CSF Aβ40, Aβ42, tau, and phospho-tau 181) and v...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, R. Scott, Thomas, Ronald G., Craft, Suzanne, van Dyck, Christopher H., Mintzer, Jacobo, Reynolds, Brigid A., Brewer, James B., Rissman, Robert A., Raman, Rema, Aisen, Paul S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626244/
https://www.ncbi.nlm.nih.gov/pubmed/26362286
http://dx.doi.org/10.1212/WNL.0000000000002035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626244/
https://www.ncbi.nlm.nih.gov/pubmed/26362286
http://dx.doi.org/10.1212/WNL.0000000000002035

Ejemplares similares